Latest Sedatives Stories
PT. RICHMOND, Calif., Oct.
AstraZeneca has received the FDA's approval for once-daily Seroquel extended-release tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
US government scientists convened in an online chat room Tuesday to answer questions about drugs and alcohol coming from students during the National Institute on Drug Abuseâ€™s second-ever Drug Facts Chat Day.
AACHEN, Germany and CAMBRIDGE, UK, Sept. 22, 2008 (GLOBE NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM: PAI) today announces that its Phase I study with its sedative CNS 7056 has progressed to the dose levels that induce pronounced sedation.
NovaDel Pharma, a specialty pharmaceutical company, has announced that the FDA has requested an extension of up to three months on the Prescription Drug User Fee Act deadline in order to complete the review of the company's Zolpimist oral spray for the short-term treatment of insomnia.
NovaDel Pharma Inc. (AMEX: NVD) today announced that the U.S.
-- Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period -- Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation Sepracor Inc.
Using functional magnetic resonance imaging, Dutch researchers said cognitive deficits were reversed after six weeks of sleep therapy.
Analysts in the UK have reported a surge in popularity of the drug diazepam, better known as Valium, among drug users.
Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona.